A 24-Week, Randomised, Parallel-Group, Multi-Centre, Open-Label Study of the Renal Effects of Tesaglitazar in Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2011
At a glance
- Drugs Pioglitazone; Tesaglitazar
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms ARMOR
- Sponsors AstraZeneca
- 11 Nov 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 09 Aug 2006 Status change
- 04 Dec 2005 New trial record.